Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA.
Duke Clinical Research Institute, Durham, North Carolina, USA. Electronic address: https://twitter.com/ajnelson.
J Am Coll Cardiol. 2022 May 10;79(18):1849-1857. doi: 10.1016/j.jacc.2022.02.046.
Cardiovascular disease is a leading cause of morbidity and mortality in individuals with type 2 diabetes mellitus. These high-risk patients benefit from aggressive risk factor management, with blood pressure and low-density lipoprotein-cholesterol treatment, glycemic control, kidney protection, and lifestyle intervention. There are several recommendation and guideline documents across cardiology, endocrinology, nephrology, and general medicine professional societies from the United States and Europe with recommendations for cardiovascular risk reduction in patients with type 2 diabetes mellitus. Although there are some noteworthy differences, particularly in risk stratification, low-density lipoprotein-cholesterol and blood pressure treatment targets, and the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, overall there is considerable alignment across recommendations from different professional societies.
心血管疾病是 2 型糖尿病患者发病率和死亡率的主要原因。这些高危患者受益于积极的危险因素管理，包括血压和低密度脂蛋白胆固醇治疗、血糖控制、肾脏保护和生活方式干预。来自美国和欧洲的心脏病学、内分泌学、肾脏病学和普通医学专业学会的多项推荐和指南文件为 2 型糖尿病患者的心血管风险降低提供了建议。尽管存在一些值得注意的差异，特别是在风险分层、低密度脂蛋白胆固醇和血压治疗目标以及钠-葡萄糖共转运蛋白-2 抑制剂和胰高血糖素样肽-1 受体激动剂的使用方面，但不同专业学会的建议总体上有相当大的一致性。
